Kelzy (Dienogest, Ethinylestradiol | Lactose)

The two hormones act synergistically: ethinylestradiol stabilises the endometrium and suppresses follicle‑stimulating hormone release, while dienogest, a progestogen, thickens cervical mucus and alters the endometrial lining. Together they inhibit ovulation by reducing luteinising hormone secretion, creating an environment that prevents fertilisation and implantation.

The dosing regimen for Kelzy is determined by the prescribing healthcare professional. Typically, one tablet is taken orally each day at the same time, but the exact schedule and duration are individualized based on the patient’s medical history and clinical response.

Kelzy is classified as pregnancy category X, meaning it must not be used during pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as hormonal components may pass into breast milk and affect the infant. Women should use an alternative method if they become pregnant or plan to breastfeed.

To place an order, submit an enquiry on the Kelzy product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kelzy contains dienogest, a newer progestogen with a lower androgenic profile, combined with ethinylestradiol. Compared with older formulations that use levonorgestrel, Kelzy may offer improved control of acne and less impact on lipid metabolism, while providing comparable contraceptive efficacy and cycle‑regulating benefits.

Kelzy tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children. Do not use tablets that have been exposed to excessive heat or humidity.

Kelzy is taken orally as a single tablet once daily, preferably at the same time each day. It can be taken with or without food. Consistent daily intake is essential to maintain contraceptive effectiveness and to achieve stable cycle regulation.

The most serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare but severe complications may also involve severe hypertension, liver tumours, and allergic reactions like anaphylaxis. Patients should seek immediate medical attention if they experience chest pain, sudden shortness of breath, severe headache, or visual changes.

Kelzy is contraindicated in women who are pregnant, have a history of thromboembolic disorders, smoke heavily (especially over age 35), have estrogen‑dependent tumours, uncontrolled hypertension, severe liver disease, or known hypersensitivity to any component of the tablet. A thorough medical assessment is required before initiating therapy.